This report collects all COVID-19 long-term care facilities (LTCF) data reported to ECDC from 2021 and concludes the EU/EEA LTCF COVID-19 specific surveillance data collection from 2021-2023.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 17-23 March 2024 and includes updates on SARS-CoV-2 variant classification, hepatitis A, pertussis, invasive Group A streptococcal infection, chikungunya, dengue, poliomyelitis, western equine encephalitis and cholera.
This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
In 2022, 30 EU/EEA countries reported 4 548 cases of hepatitis A. The EU/EEA notification rate was one case per 100 000 population. Twenty EU/EEA countries had notification rates below one case per 100 000 population. The countries with the highest notification rates were Hungary (5.5), Croatia (5.3) Romania (4.8), and Bulgaria (4.4).
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 17-23 December 2023 and includes updates on cholera, SARS-CoV-2 variant classification, avian influenza in fur farms, hepatitis A, pertussis, a cluster of extensively drug-resistant Shigella Sonnei among men who have sex with men, and an overview of respiratory virus epidemiology in the EU/EE.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 October 2023 and includes updates on hepatitis A, influenza A(H5N1), COVID-19, the Rugby World Cup 2023, West Nile virus, measles and diphtheria.
Outsourced microbiological support to hospital-based surveillance of CDI aims to increase the capacity of laboratories in EU/EEA Member States to perform diagnostic practices with high diagnostic accuracy and acquire comparable typing data from C. difficile isolates.
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.
In 2018, 9 860 (7.8%) of patients staying in an intensive care unit (ICU) for more than two days presented with at least one ICU-acquired healthcare-associated infection (HAI) under surveillance (pneumonia, bloodstream infection or urinary tract infection).